Intra-Cellular Therapies, Inc.
ITCI · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$16,885 | -$26,324 | -$16,220 | -$15,247 |
| Dep. & Amort. | $109 | $138 | $129 | $132 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $16,333 | $17,489 | $16,370 | $13,843 |
| Change in WC | -$9,667 | -$15,999 | $2,093 | -$30,524 |
| Other Non-Cash | -$2,968 | -$1,829 | $25,216 | $29,345 |
| Operating Cash Flow | -$13,078 | -$26,525 | $542 | -$34,116 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $427 | -$696 | -$53 | $0 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$257,602 | -$312,507 | -$88,524 | -$81,046 |
| Inv. Sales/Matur. | $107,283 | $104,000 | $96,343 | $97,225 |
| Other Inv. Act. | $0 | $0 | $7,819 | $16,179 |
| Investing Cash Flow | -$149,892 | -$209,203 | $7,766 | $16,179 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $0 | -$12,082 | $545,179 | $9,989 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $5,606 | $6,734 | $545,179 | $9,989 |
| Financing Cash Flow | $5,606 | $6,734 | $545,179 | $9,989 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$157,364 | -$228,994 | $553,487 | -$7,948 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $466,062 | $695,056 | $141,569 | $149,517 |
| End Cash | $308,698 | $466,062 | $695,056 | $141,569 |
| Free Cash Flow | -$12,651 | -$27,221 | $489 | -$34,116 |